Приоритетные аспекты изучения проблемы ТБ/ВИЧ в условиях ...

Приоритетные аспекты изучения проблемы ТБ/ВИЧ в условиях высокой распространенности ВИЧ-инфекции и ограниченных ресурсов192 Marais BJ, Gie RP, Hesseling AC et al. A refinedsymptom-based approach to diagnose pulmonarytuberculosis in children. Pediatrics, 2006,118(5):e1350-1359.193 Madhi SA, Huebner RE, Doedens L et al. HIV-1 coinfectionin children hospitalised with tuberculosisin South Africa. International Journal of Tuberculosisand Lung Disease, 2000, 4(5):448-454.194 Schaaf HS, Geldenduys A, Gie RP et al. Culturepositivetuberculosis in human immunodeficiencyvirus type 1-infected children. Pediatric InfectiousDisease Journal, 1998, 17(7):599-604.195 Kumar A, Upadhyay S, Kumari G. ClinicalPresentation, treatment outcome and survivalamong the HIV infected children with cultureconfirmed tuberculosis. Current HIV Research, 2007,5(5):499-504.196 Graham SM, Coulter JB, Gilks CF. Pulmonary diseasein HIV-infected African children. InternationalJournal of Tuberculosis and Lung Disease, 2001,5(1):12-23.197 Liebeschuetz S, Bamber S, Ewer K et al. Diagnosis oftuberculosis in South African children with a T-cellbasedassay: a prospective cohort study. Lancet,2004, 364(9452):2196-2203.198 Walters E, Cotton MF, Rabie H et al. Clinicalpresentation and outcome of tuberculosis inhuman immunodeficiency virus infected childrenon anti-retroviral therapy. BMC Pediatrics, 2008, 8:1.199 Schaaf HS, Willemse M, Cilliers K et al. Rifampinpharmacokinetics in children, with and withouthuman immunodeficiency virus infection,hospitalized for the management of severe formsof tuberculosis. BMC Medicine, 2009, 7:19.200 Edmonds A, Lusiama J, Napravnik S et al. Antiretroviraltherapy reduces incident tuberculosisin HIV-infected children. International Journal ofEpidemiology, 2009, 38(6):1612-1621.201 Ren Y, Nuttall JJ, Egbers C et al. Effect of rifampicinon lopinavir pharmacokinetics in HIV-infectedchildren with tuberculosis. Journal of AcquiredImmune Deficiency Syndromes, 2008, 47(5):566-569.202 Ren Y, Nuttall JJ, Eley BS et al. Effect of rifampicinon efavirenz pharmacokinetics in HIV-infectedchildren with tuberculosis. Journal of AcquiredImmune Deficiency Syndromes, 2009, 50(5):439-443.203 Martinson NA, Morris L, Gray G et al. Selectionand persistence of viral resistance in HIV-infectedchildren after exposure to single-dose nevirapine.Journal of Acquired Immune Deficiency Syndromes,2007, 44(2):148-153.204 Lockman S, Shapiro RL, Smeaton LM et al. Responseto antiretroviral therapy after a single, peripartumdose of nevirapine. New England Journal ofMedicine, 2007, 356(2):135-147.205 NIAID. Ritonavir-boosted Lopinavir Proves superiorto Nevirapine in HIV-Infected Infants Who ReceivedSingle-Dose Nevirapine at Birth. National Institute ofAllergy and Infectious Diseases, 2009. http://www3.niaid.nih.gov/news/newsreleases/2009/P1060.htm206 Puthanakit T, Oberdorfer P, Akarathum N etal. Immune reconstitution syndrome afterhighly active antiretroviral therapy in humanimmunodeficiency virus-infected thai children.Pediatric Infectious Disease Journal, 2006, 25(1):53-58.207 Zampoli M, Kilborn T, Eley B. Tuberculosis duringearly antiretroviral-induced immune reconstitutionin HIV-infected children. International Journal ofTuberculosis and Lung Disease, 2007, 11(4):417-423.208 Soeters M, de Vries AM, Kimpen JL et al. Clinicalfeatures and outcome in children admitted to a TBhospital in the Western Cape--the influence of HIVinfection and drug resistance. South African MedicalJournal, 2005, 95(8):602-606.209 Drobac PC, Mukherjee JS, Joseph JK et al.Community-based therapy for children withmultidrug-resistant tuberculosis. Pediatrics, 2006,117(6):2022-2029.210 Pillay T, Khan M, Moodley J et al. Perinataltuberculosis and HIV-1: considerations for resourcelimitedsettings. Lancet Infectious Diseases, 2004,4(3):155-165.211 Pillay T, Khan M, Moodley J et al. The increasingburden of tuberculosis in pregnant women,newborns and infants under 6 months of agein Durban, KwaZulu-Natal. South African MedicalJournal, 2001, 91(11):983-987.47